Home - Annals of Lymphoma

Reviewer of the Month (2024)

In 2024, AOL reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

In the last 30 years, the standard treatments for PCNSL at Memorial Sloan Kettering Cancer Center (MKSCC) have evolved. HDMTX-containing chemotherapy regimen (mainly HDMTX dosed at 3.5 g/m2, vincristine, and procarbazine) has been predominantly used as mainstay treatment. Around 2006, rituximab was added to this regimen more routinely. Moreover, the number of HDMTX doses administered has increased in recent years. The purpose of this retrospective analysis of a large newly diagnosed PCNSL patient population was to investigate if shifts in standard treatment practices were associated with improvement in clinical outcomes.

Complete renal and haematological remission in a case of mantle cell lymphoma associated paraneoplastic focal segmental glomerulosclerosis with ibrutinib: a case report and review of literature

A 73-year-old gentleman presented with 2-month history of bilateral pedal oedema with frothy urine. Examination revealed generalized lymphadenopathy with hepatosplenomegaly. Twenty-four-hour urine protein was 11 grams/total volume, suggesting nephrotic syndrome. There were atypical circulating lymphocytes in the blood. Flowcytometry and cytogenetic studies from bone marrow aspirate and histopathology of lymph node biopsy confirmed the diagnosis of MCL. Kidney biopsy revealed FSGS. The patient was treated with ibrutinib 560 mg once daily considering his age and preference for oral therapy. At the end of two years of follow-up the patient is in complete remission for both MCL and FSGS.

Central Nervous System Lymphomas

In the last decade, international cooperation established consolidated therapeutic guidelines and advanced our learning in some peculiar settings, like vitreoretinal lymphoma and neurolymphomatosis. Basic research critically contributed to these achievements, mostly on activated tumor pathways that could represent suitable targets for novel therapies. The efforts of several multidisciplinary experts led to relevant improvement in outcome and quality of life of patients affected by this dismal disease. Many of these internationally recognized experts contributed to summarize the current knowledge, discuss evidence, provide recommendations, and foresee possible scenarios in this special series of Annals of Lymphoma.

Welcome to Annals of Lymphoma

During my formative years, a textbook of hematology would contain a single, rather brief, chapter on lymphomas. Within the pages would be clinical and pathologic descriptions in broad terms relating to a limited number of recognized histologic subtypes. As our knowledge increased, the chapters were separated into Hodgkin and non-Hodgkin, and then the latter into B- and T-cell. Treatment strategies from that period relied heavily on radiation therapy, but eventually active systemic treatment was available, although founded on those derivatives of mustard gas, the alkylating agents, as well as corticosteroids, and a series of other non-specific cytotoxic drugs. Means to assess response were rudimentary and variable, including radiographs, lymphangiograms and ultrasounds. It was totally unclear why some patients with a similar histologic morphology would be cured, whereas others were resistant to similar treatments. In this context, the glacial speed of journal publications was sufficient.

‹ ›

About aol

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: aol@amegroups.com
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Case Report

Complete renal and haematological remission in a case of mantle cell lymphoma associated paraneoplastic focal segmental glomerulosclerosis with ibrutinib: a case report and review of literature

Urmimala Bhattacharjee, Sarthak Wadhera, Arihant Jain, Ritambhra Nada, Sreejesh Sreedharanunni, Man Updesh Singh Sachdeva, Pankaj Malhotra

Annals of Lymphoma

2023;

(30 March 2023)

PDF Full Text (1050) Reporting Checklist COI Form Open Access

Original Article

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

Prakirthi Yerram, Samantha N. Reiss, Lisa Modelevsky, Lauren Schaff, Anne S. Reiner, Katherine S. Panageas, Christian Grommes

Annals of Lymphoma

2023;

(28 February 2023)

PDF Full Text (1281) Reporting Checklist Data Sharing Statement COI Form Open Access

Review Article

State of the art in the diagnosis, biology and treatment of primary mediastinal B-cell lymphoma: a review

Vincent Camus, Fanny Drieux, Fabrice Jardin

Annals of Lymphoma

2022;

(30 December 2022)

PDF Full Text (3559) COI Form Open Access

Review Article

Older patients with mantle cell lymphoma: initial and subsequent therapies—a narrative review

Sowjanya Vuyyala, Tycel Jovelle Phillips

Annals of Lymphoma

2022;

(30 December 2022)

PDF Full Text (1812) Reporting Checklist COI Form Open Access

Review Article

Clinical geriatric assessment in older patients with lymphoma: a narrative review

Giulia Soverini, Alessandra Tucci

Annals of Lymphoma

2022;

(30 September 2022)

PDF Full Text (1452) Reporting Checklist COI Form Open Access

Review Article

Age is just a number: managing relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in older patients

Danielle S. Wallace, Patrick M. Reagan

Annals of Lymphoma

2022;

(30 September 2022)

PDF Full Text (2828) COI Form Open Access

Review Article

Initial treatment of elderly population with aggressive lymphoma: a narrative review of current evidence and future directions

Behzad Amoozgar, Brad S. Kahl

Annals of Lymphoma

2022;

(30 September 2022)

PDF Full Text (3622) Reporting Checklist COI Form Open Access

Review Article

Transplant and chimeric antigen receptor T-cell therapies in elderly patients with lymphoma, a narrative review

I. Brian Greenwell, Parastoo B. Dahi

Annals of Lymphoma

2022;

(30 September 2022)

PDF Full Text (1836) Reporting Checklist COI Form Open Access

Editorial

Preface: virus-associated lymphomas

Christopher P. Fox, Claire Shannon-Lowe

Annals of Lymphoma

2022;

(30 September 2022)

PDF Full Text (981) COI Form Open Access

Review Article

Diffuse large B-cell lymphoma among the elderly: a narrative review of current knowledge and future perspectives

Tove Wästerlid, Shannon Murphy, Diego Villa, Tarec C. El-Galaly

Annals of Lymphoma

2022;

(30 June 2022)

PDF Full Text (7620) Reporting Checklist COI Form Open Access

Review Article

Adoptive cellular immunotherapy for Epstein-Barr virus-associated lymphoproliferative disease

Birte Wistinghausen, Hema Dave, Catherine M. Bollard

Annals of Lymphoma

2022;

(30 June 2022)

PDF Full Text (1934) COI Form Open Access

Editorial

The diversity challenges in follicular lymphoma

Mark Roschewski, Carla Casulo

Annals of Lymphoma

2022;

(30 June 2022)

PDF Full Text (979) COI Form Open Access

Case Report

The gamma delta lymphomas: an Australian multi-centre case series

Sean Harrop, Pietro Di Ciaccio, Nicole Wong Doo, Tara Cochrane, Belinda A. Campbell, Nada Hamad, Michael Dickinson, Carrie Van Der Weyden, Henry Miles Prince

Annals of Lymphoma

2022;

(30 March 2022)

PDF Full Text (3693) Reporting Checklist COI Form Open Access

Case Report

Complete response of relapsed adult T-cell lymphoma leukemia to a Bcl-2 inhibitor: a case report

Alessandra Petrillo, Maher Albitar, Tatyana Feldman

Annals of Lymphoma

2022;

(30 March 2022)

PDF Full Text (1984) Reporting Checklist COI Form Open Access

Review Article

Primary diffuse large B-cell lymphoma of the central nervous system: molecular and biological features of neoplastic cells

Francesco Bertoni, Manuel Montesinos-Rongen

Annals of Lymphoma

2022;

(30 March 2022)

PDF Full Text (7587) COI Form Open Access

Editorial

Primary central nervous system lymphoma

Andrés J. M. Ferreri, Maurilio Ponzoni

Annals of Lymphoma

2021;

(30 December 2021)

PDF Full Text (744) COI Form Open Access

Case Report

Daratumumab as first line therapy in primary effusion lymphoma: a case report

Kaitlyn Wiltshire, David Kliman, Joanne Tan, Hang Quach, Anna Kalff, Rhoda Cameron, George Grigoriadis, Harshal Nandurkar

Annals of Lymphoma

2021;

(30 December 2021)

PDF Full Text (1277) Reporting Checklist COI Form Open Access

Review Article

Minimal residual disease in follicular lymphoma

Christiane Pott, Dominique Wellnitz, Marco Ladetto

Annals of Lymphoma

2021;

(30 December 2021)

PDF Full Text (2962) COI Form Open Access

Review Article

From pathobiology to targeted treatment in Epstein Barr virus related T cell and Natural Killer cell lymphoproliferative diseases

Alexander Glover, Claire Shannon-Lowe

Annals of Lymphoma

2021;

(30 December 2021)

PDF Full Text (3042) COI Form Open Access

Review Article

The contribution of ebv to the pathogenesis of classical hodgkin lymphoma

Katerina Vrzalikova, Matthew Pugh, Lucia Mundo, Paul Murray

Annals of Lymphoma

2021;

(30 September 2021)

PDF Full Text (7155) COI Form Open Access

View more articles

Review Article

The role of pathologic testing in the diagnosis and management of patients with diffuse large B cell lymphoma: a narrative review

Michael Schneider, Daniel Landsburg

Published online: 20 March 2024

Review Article

Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation

Melody Becnel, Christopher R. Flowers, Loretta J. Nastoupil

Review Article

Hodgkin lymphoma and PD-1 blockade: an unfinished story

Reid Merryman, Philippe Armand

Review Article

Responses and response evaluation of immune checkpoint inhibitors in lymphoma

Theodora Anagnostou, Stephen M. Ansell

Review Article

Unmet needs in histological transformation of follicular lymphoma: a clinical and biological review

Miguel Alcoceba, Sara Alonso-Álvarez, María García-Álvarez, Alejandro Martín, M. Dolores Caballero

Journal Highlight more

Annals of Lymphoma, is an open access, international, peer-reviewed electronic journal, and openly distributed worldwide. It publishes articles that describe advances in basic and translational science, and clinical findings relating to human lymphoma. Specific areas of interest include, but are not limited to, epidemiology, biology, genetics, immunology, diagnosis, treatment, and measures of assessment of response.